ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Corvex Dumps $57M in Illumina; Uber COO Buys In

By ORTEX News · Edited by , Editor, ORTEX News1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Activist fund Corvex Management filed disclosures this month showing it sold over $57 million worth of ILMN shares between September 2 and 4. The filings also reveal Corvex principal Keith Meister personally sold a further $85 million in late August. Combined, that's well over $140 million in exits from one activist investor in less than two weeks — a striking reversal for a fund that holds a board seat.

Corvex's seat on Illumina's board makes these sales especially notable. Board-level insiders rarely exit in size without a strategic reason. Illumina's short interest sits at 7% of free float, and the stock has plenty of available borrow.

On the buy side, UBER President and COO Andrew MacDonald filed purchases totalling over $5.3 million in open-market buys on September 4. That's a discretionary, non-planned purchase by the company's second-highest-ranking executive. With Uber's market cap at $143 billion, the dollar amount is modest — but the signal is strong.

Also catching attention: two directors at psychedelic-drug biotech HELP (Cybin Inc.) each bought around $1.2 million in shares on September 3–4. Cluster buying by board members is a classic bullish insider signal.

NMI Holdings CEO Adam Pollitzer filed a $7.7 million sale on September 4. No 10b5-1 plan was indicated in the available data, making it a trade worth monitoring.

Insider data sourced from ORTEX. This is not financial advice.

Stocks in this article

How this article was generated

Generated
23 Sept 2026, 20:12
Prompt version
v1.0
Data sources
Institutional positioning

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.